A signature for immune response correlates with HCV treatment outcome in Caucasian subjects

Brian J Hare; Eric Haseltine; Mark Fleming; Daniel Chelsky; Laura McIntosh; Rene Allard; Martyn Botfield

doi:10.1016/j.dib.2015.01.009

A signature for immune response correlates with HCV treatment outcome in Caucasian subjects

Data Brief. 2015 Feb 11:3:56-61. doi: 10.1016/j.dib.2015.01.009. eCollection 2015 Jun.

Authors

Brian J Hare¹, Eric Haseltine¹, Mark Fleming¹, Daniel Chelsky², Laura McIntosh², Rene Allard², Martyn Botfield¹

Affiliations

¹ Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
² Caprion Proteomics, Montreal, Quebec, Canada H2X 3Y7.

Abstract

This data article contains Supplementary material for a published research article describing a whole-blood proteomic signature that predicts treatment outcome for subjects infected with hepatitis C virus (HCV) [1]. The proteomic signature is derived from whole-blood samples from subjects infected with HCV. The article includes detailed experimental and computational methods used in the analysis. The article also includes tables of demographic and other information about the subjects. Finally, the article includes several figures and tables showing detailed results of the analyses (e.g. lists of identified proteins and coefficients/ROC curves for the regression models).